FAQs
Yes, Uniferon 200 is the subject of a Center for Veterinary Medicine of the U.S. Food an Drug Administration (CVM/FDA) approved product registration, which is classified as an approved New Animal Drug Application (NADA). The product registration is identified as NADA #134-708.
Yes, Uniferon 200 is focused entirely on the treatment and prevention of sub-clinical and full-scale iron deficiency anemia of baby pigs, and the product is manufactured and marketed as a sterile injectable product.
Simply e-mail us at uniferon.us@pharmacosmos.com or call (908) 769-7045.
Pharmacosmos A/S is a privately owned, independent pharmaceutical company located in Holbaek, Denmark. Pharmacosmos A/S is a leading global supplier of iron therapy for human and veterinary use and has been supplying the U.S. veterinary market with the high-quality, FDA-approved raw material 200 mg/mL nonsterile iron hydrogenated bulk dextran liquid since the mid-1980’s.
Today, Pharmacosmos A/S is a leading specialist in iron therapy and associated pharmaceutical research, and the company develops, manufactures and markets innovative therapies for the treatment of iron deficiency in both human and animal medicine.
Pharmacosmos, Inc. is a wholly-owned U.S. subsidiary of Pharmacosmos A/S and it is the sponsor / owner of the FDA approved New Animal Drug Application (NADA) #134-708 for Uniferon 200.
The Uniferon 200 finished product is manufactured for Pharmacosmos, Inc., a U.S. subsidiary that is the sponsor / owner of the Uniferon 200 FDA approved product registration, by a U.S. FDA approved contract manufacturer that was specifically approved by CVM/FDA to do so.
The 200 mg/mL non-sterile iron hydrogenated dextran bulk liquid active pharmaceutical ingredient (API) utilized in the production of the Uniferon® 200 final dosage form (FDF) product is manufactured in the FDA approved Pharmacosmos A/S facility in Holbaek, Denmark.